![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
PE Gilbert and WR Martin
A series of morphine-like and nalorphine-like drugs were studied in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog. In the nondependent dog, three profiles of activity were found which could be utilized to distinguish between morphine, WIN 35, 197-2 and cyclazocine. Propiram, a prototypic partial agonist of the morphine type, produced morphine-like effects in nondependent dogs and both precipitated and suppressed abstinence in cyclazocine-dependent dogs as was needed to precipitate abstinence in morphine-dependent dogs. WIN 35, 197-2, a strong agonist in the guinea-pig ileum which has been shown to be resistant to antagonism by naloxone, neither precipitated nor suppressed morphine abstinence but suppressed cyclazocine abstinence. In the nondependent dog, it depressed the flexor reflex but not skin twitch reflex. Cyclazocine altered reflex activity much like WIN 35, 197-2 but produced tachycardia, tachypnea, mydriasis and canine delirum. The morphine and cyclazocine precipitated and withdrawal abstinence syndromes were qualitatively different. Twenty times as much naltrexone was needed to precipitate abstinence in morphine-dependent dogs. Nalorphine both precipitated and suppressed cyclazocine abstinence and appeared to be a partial agonist of the nalorphine-type. Morphine suppressed the cyclazocine abstinence syndrome. Cross-tolerance was not observed in ketocyclazocine-dependent dogs. These data are consistent with the hypothesis that there are strong and partial agonists of the mu and kappa types, and further, that physical dependence on morphine and cyclazocine is mediated through different receptors. WIN 35, 197-2 appears to be a pure strong agonist of the kappa type. Cyclazocine is a mu antagonist and mixed kappa and sigma agonist.
This article has been cited by other articles:
|
|
 |
|
  I. D. Alves, S. M. Cowell, Z. Salamon, S. Devanathan, G. Tollin, and V. J. Hruby Different Structural States of the Proteolipid Membrane Are Produced by Ligand Binding to the Human {delta}-Opioid Receptor as Shown by Plasmon-Waveguide Resonance Spectroscopy Mol. Pharmacol., May 1, 2004; 65(5): 1248 - 1257. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. T. Williams, M. J. Christie, and O. Manzoni Cellular and Synaptic Adaptations Mediating Opioid Dependence Physiol Rev, January 1, 2001; 81(1): 299 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Quock, T. H. Burkey, E. Varga, Y. Hosohata, K. Hosohata, S. M. Cowell, C. A. Slate, F. J. Ehlert, W. R. Roeske, and H. I. Yamamura The delta -Opioid Receptor: Molecular Pharmacology, Signal Transduction, and the Determination of Drug Efficacy Pharmacol. Rev., September 1, 1999; 51(3): 503 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Vaupel and D. R. Jasinski l-alpha -Acetylmethadol, l-alpha -Acetyl-N-normethadol and l-alpha -Acetyl-N,N-dinormethadol: Comparisons with Morphine and Methadone in Suppression of the Opioid Withdrawal Syndrome in the Dog J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 833 - 842. [Abstract] [Full Text]
|
|
|
|
|
|
C. A. Paronis and J. H. Woods Ventilation in Morphine-Maintained Rhesus Monkeys. I: Effects of Naltrexone and Abstinence-Associated Withdrawal, J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 348 - 354. [Abstract] [Full Text]
|
|
|
|
|
|
S. Chakrabarti, W. Yang, P.-Y. Law, and H. H. Loh The µ-Opioid Receptor Down-Regulates Differently from the delta -Opioid Receptor: Requirement of a High Affinity Receptor/G Protein Complex Formation Mol. Pharmacol., July 1, 1997; 52(1): 105 - 113. [Abstract] [Full Text]
|
|
|
|
 |
|
 A.J. Stoessl Peptide-dopamine interactions in the central nervous system: implications for neuropsychiatric disorders J Psychopharmacol, January 1, 1989; 3(2): 99 - 120. [PDF]
|
|
|
|
 |
|
 C Chavkin, I. James, and A Goldstein Dynorphin is a specific endogenous ligand of the kappa opioid receptor Science, January 22, 1982; 215(4531): 413 - 415. [Abstract] [PDF]
|
|
|
|
|
|
J. Hiller, L. Angel, and E. Simon Multiple opiate receptors: alcohol selectively inhibits binding to delta receptors Science, October 23, 1981; 214(4519): 468 - 469. [Abstract] [PDF]
|
|
|
|
|
|
O. Snead 3rd and L. Bearden Anticonvulsants specific for petit mal antagonize epileptogenic effect of leucine enkephalin Science, November 28, 1980; 210(4473): 1031 - 1033. [Abstract] [PDF]
|
|
|
|
|
|
A Cowan, E. Geller, and M. Adler Classification of opioids on the basis of change in seizure threshold in rats Science, October 26, 1979; 206(4417): 465 - 467. [Abstract] [PDF]
|
|
|
|
|
|
H Frenk, B. McCarty, and J. Liebeskind Different brain areas mediate the analgesic and epileptic properties of enkephalin Science, April 21, 1978; 200(4339): 335 - 337. [Abstract] [PDF]
|
|
|
|
|
|
Y. Jacquet, W. Klee, K. Rice, I Iijima, and J Minamikawa Stereospecific and nonstereospecific effects of (+)- and (-)-morphine: evidence for a new class of receptors? Science, November 25, 1977; 198(4319): 842 - 845. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
